✦ LIBER ✦

A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?

✍ Scribed by Hasselbalch, Hans C.

Book ID: 122472349
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 475 KB
Volume: 38
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2013.07.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chronic inflammation as a promotor of mu

Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?

✍ Hasselbalch, Hans Carl 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 284 KB

TET2 mutations and their clinical correl

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

✍ Tefferi, A; Pardanani, A; Lim, K-H; Abdel-Wahab, O; Lasho, T L; Patel, J; Gangat 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 164 KB

A phase II trial of tipifarnib in myelof

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia

✍ Mesa, R A; Camoriano, J K; Geyer, S M; Wu, W; Kaufmann, S H; Rivera, C E; Erlich 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 139 KB

Different involvement of the megakaryocy

Different involvement of the megakaryocytic lineage by the JAK2V617Fmutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis

✍ Kais Hussein; Kai Brakensiek; Guntram Buesche; Thomas Buhr; Birgitt Wiese; Hans 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 278 KB

Leukemogenic risk of hydroxyurea therapy

Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

✍ Nand, Sucha; Stock, Wendy; Godwin, John; Fisher, Susan Gross 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB 👁 2 views

In polycythemia Vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%. This risk has been estimated to be 1-5.9% with hydroxyurea (HU) therapy. When compared with historical controls, the risk with use of HU does not a

IDH1 and IDH2 mutation studies in 1473 p

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

✍ Tefferi, A; Lasho, T L; Abdel-Wahab, O; Guglielmelli, P; Patel, J; Caramazza, D; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 460 KB